SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

Page 1 <img data-url='document/sabcs-2019-oncoletter-lcm-34-o-nodes-tumor-andor-pgrve-64-pertuzumab-erve.html?page=1' data-page='1' class='cut-thumb lazyload' alt='Page 1: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader033.cupdf.com/reader033/viewer/2022042321/5f0b0d9c7e708231d42e9e69/html5/thumbnails/1.jpg' width='140' height='200' /> SABCS 2019

Page 2 <img data-url='document/sabcs-2019-oncoletter-lcm-34-o-nodes-tumor-andor-pgrve-64-pertuzumab-erve.html?page=2' data-page='2' class='cut-thumb lazyload' alt='Page 2: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader033.cupdf.com/reader033/viewer/2022042321/5f0b0d9c7e708231d42e9e69/html5/thumbnails/2.jpg' width='140' height='200' /> SABCS 2019

Page 3 <img data-url='document/sabcs-2019-oncoletter-lcm-34-o-nodes-tumor-andor-pgrve-64-pertuzumab-erve.html?page=3' data-page='3' class='cut-thumb lazyload' alt='Page 3: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader033.cupdf.com/reader033/viewer/2022042321/5f0b0d9c7e708231d42e9e69/html5/thumbnails/3.jpg' width='140' height='200' /> SABCS 2019

Page 4 <img data-url='document/sabcs-2019-oncoletter-lcm-34-o-nodes-tumor-andor-pgrve-64-pertuzumab-erve.html?page=4' data-page='4' class='cut-thumb lazyload' alt='Page 4: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader033.cupdf.com/reader033/viewer/2022042321/5f0b0d9c7e708231d42e9e69/html5/thumbnails/4.jpg' width='140' height='200' /> SABCS 2019

Page 5 <img data-url='document/sabcs-2019-oncoletter-lcm-34-o-nodes-tumor-andor-pgrve-64-pertuzumab-erve.html?page=5' data-page='5' class='cut-thumb lazyload' alt='Page 5: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader033.cupdf.com/reader033/viewer/2022042321/5f0b0d9c7e708231d42e9e69/html5/thumbnails/5.jpg' width='140' height='200' /> SABCS 2019

Page 6 <img data-url='document/sabcs-2019-oncoletter-lcm-34-o-nodes-tumor-andor-pgrve-64-pertuzumab-erve.html?page=6' data-page='6' class='cut-thumb lazyload' alt='Page 6: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader033.cupdf.com/reader033/viewer/2022042321/5f0b0d9c7e708231d42e9e69/html5/thumbnails/6.jpg' width='140' height='200' /> SABCS 2019

Page 7 <img data-url='document/sabcs-2019-oncoletter-lcm-34-o-nodes-tumor-andor-pgrve-64-pertuzumab-erve.html?page=7' data-page='7' class='cut-thumb lazyload' alt='Page 7: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader033.cupdf.com/reader033/viewer/2022042321/5f0b0d9c7e708231d42e9e69/html5/thumbnails/7.jpg' width='140' height='200' /> SABCS 2019

Page 8 <img data-url='document/sabcs-2019-oncoletter-lcm-34-o-nodes-tumor-andor-pgrve-64-pertuzumab-erve.html?page=8' data-page='8' class='cut-thumb lazyload' alt='Page 8: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader033.cupdf.com/reader033/viewer/2022042321/5f0b0d9c7e708231d42e9e69/html5/thumbnails/8.jpg' width='140' height='200' /> SABCS 2019

Page 9 <img data-url='document/sabcs-2019-oncoletter-lcm-34-o-nodes-tumor-andor-pgrve-64-pertuzumab-erve.html?page=9' data-page='9' class='cut-thumb lazyload' alt='Page 9: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader033.cupdf.com/reader033/viewer/2022042321/5f0b0d9c7e708231d42e9e69/html5/thumbnails/9.jpg' width='140' height='200' /> SABCS 2019

Page 10 <img data-url='document/sabcs-2019-oncoletter-lcm-34-o-nodes-tumor-andor-pgrve-64-pertuzumab-erve.html?page=10' data-page='10' class='cut-thumb lazyload' alt='Page 10: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader033.cupdf.com/reader033/viewer/2022042321/5f0b0d9c7e708231d42e9e69/html5/thumbnails/10.jpg' width='140' height='200' /> SABCS 2019

Page 11 <img data-url='document/sabcs-2019-oncoletter-lcm-34-o-nodes-tumor-andor-pgrve-64-pertuzumab-erve.html?page=11' data-page='11' class='cut-thumb lazyload' alt='Page 11: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader033.cupdf.com/reader033/viewer/2022042321/5f0b0d9c7e708231d42e9e69/html5/thumbnails/11.jpg' width='140' height='200' /> SABCS 2019

Page 12 <img data-url='document/sabcs-2019-oncoletter-lcm-34-o-nodes-tumor-andor-pgrve-64-pertuzumab-erve.html?page=12' data-page='12' class='cut-thumb lazyload' alt='Page 12: SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is' loading='lazy' src='data:image/gif;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAYAAAAfFcSJAAAADUlEQVR42mNk+P+/HgAFhAJ/wlseKgAAAABJRU5ErkJggg==' data-src='https://reader033.cupdf.com/reader033/viewer/2022042321/5f0b0d9c7e708231d42e9e69/html5/thumbnails/12.jpg' width='140' height='200' /> SABCS 2019

SABCS 2019 - oncoletter · lcm (34%) O nodes tumor and/or pgR.ve (64%) pertuzumab ER.ve and/or (64%) ER-ve (36%) Placebo Placebo Pertuzumab Placebo Pertuzumab This presentation is

Documents